ATM/ATR and SMAD3 pathways contribute to 3-indole-induced G1 arrest in cancer cells and xenograft models

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 203-208

  Huang, Sin Ming ^a,b   Lu, Kwok Tung ^a   Wang, Y I Ching ^b  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

3 Indole; ATM; ATR; Cell cycle arrest; Lung cancer cells; SMAD3; Xenograft model

Indexed keywords

3 INDOLE; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; CELL CYCLE PROTEIN; CELL DIVISION CYCLE 25 HOMOLOG A PROTEIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; DOXORUBICIN; INDOLE DERIVATIVE; REACTIVE OXYGEN METABOLITE; ROTENONE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIVISION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; COMET ASSAY; DNA DAMAGE; DNA-BINDING PROTEINS; FEMALE; G1 PHASE; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79851482754     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Danesi R, de Braud F, Fogli, de Pas TM, Di Paolo A, Curigliano G and Del Tacca M: Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 55: 57-103, 2003.
3. Mariette C, Piessen G and Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8: 545-553, 2007. (Pubitemid 46813024)
4. Bakkenist CJ and Kastan MB: Initiating cellular stress responses. Cell 118: 9-17, 2004. (Pubitemid 38902810)
5. Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196, 2001.
6. Appella E and Anderson CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764-2772, 2001. (Pubitemid 32862957)
7. Chen Y and Poon RY: The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 13: 5016-5029, 2008. (Pubitemid 351599655)
8. Liu Q, Guntuku S, Cui XS et al: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14: 1448-1459, 2000. (Pubitemid 30421838)
9. Feng XH, Liang YY, Liang M, Zhai W and Lin X: Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell 9: 133-143, 2002. (Pubitemid 34127777)
10. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D and Moustakas D: Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275: 29244-29256, 2000. (Pubitemid 32043793)
11. Millet C and Zhang YE: Roles of Smad3 in TGF-beta signaling during carcinogenesis. Crit Rev Eukaryot Gene Expr 17: 281-293, 2007.
12. Lee CH, Yao CF, Huang SM, Ko S, Tan YH, Lee-Chen GJ and Wang YC: Novel 2-step synthetic indole compound 1,1,3-tri(3-indolyl)cyclohexane inhibits cancer cell growth in lung cancer cells and xenograft models. Cancer 113: 815-825, 2008.
13. Kuo CC, Hsieh HP, Pan WY et al: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64: 4621-4628, 2004.
14. Li PY, Chang YC, Tzang BS, Chen CC, Liu YC: Antibiotic amoxicillin induces DNA lesions in mammalian cells possibly via the reactive oxygen species. Mutat Res 629: 133-139, 2007.
15. Juang SH, Lung CC, Hsu PC et al: D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. Mol Cancer Ther 6: 193-202, 2007.
16. Montecucco A, Pedrali-Noy G, Spadari S, Zanolin E and Ciarrocchi G: DNA unwinding and inhibition of T4 DNA ligase by anthracyclines. Nucleic Acids Res 16: 3907-3918, 1988.
17. Burhans WC and Heintz NH: The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 47: 1282-1293, 2009.
18. Zhang H, Gajate C, Yu LP, Fang YX and Mollinedo F: Mitochondrial-derived ROS in edelfosine-induced apoptosis in yeasts and tumor cells. Acta Pharmacol Sin 28: 888-894, 2007. (Pubitemid 46817436)
19. Selivanov VA, Vizan P, Mollinedo F, Fan TW, Lee PW and Cascante M: Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis. BMC Syst Biol 4: 135-145, 2010.
20. Cordero MD, Sanchez-Alcazar JA, Bautista-Ferrufino MR et al: Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs. Anticancer Drugs 21: 932-944, 2010.
21. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
22. Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
23. Sato K, Ito K, Kohara H, Yamaguchi Y, Adachi K and Endo H: Negative regulation of catalase gene expression in hepatoma cells. Mol Cell Biol 12: 2525-2533, 1992.
24. Hasegawa Y, Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K and Amino N: Decreased expression of glutathione peroxidase mRNA in thyroid anaplastic carcinoma. Cancer Lett 182: 69-74, 2002. (Pubitemid 34518658)
25. Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004. (Pubitemid 38736063)
26. Fojo T and Bates S: Strategies for reversing drug resistance. Oncogene 22: 7512-7523, 2003. (Pubitemid 37487173)
27. Ray D, Terao Y, Nimbalkar D et al: Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 25: 3338-3347, 2005. (Pubitemid 40464333)
28. Nemajerova A, Talos F, Moll UM and Petrenko O: Rb function is required for E1A-induced S-phase checkpoint activation. Cell Death Differ 15: 1440-1449, 2008.
29. Broude EV, Swift ME, Vivo C, Chang BD, Daris BM, Kalurupalle S, Blagosklonny MV and Roninson IB: p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 26: 6954-6958, 2007.